SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
At least 171 measles cases confirmed in 9 states, CDC data shows - 2Poll: Most are satisfied with their health insurance, but a quarter report denials or delays
- 3IDF bans Android phones for senior officers, iPhones now mandatory, Army Radio reports
- 4Guns N' Roses 2026 Tour: How to get tickets, presale times, prices and more
- 5AfD in Brandenburg takes back suit against the intelligence service
- Israel's Druze use AI to present to UN testimonies of 'sexual terrorism' against Syrian Druze women
- Fundamental Monetary Guidance for Going into Business
- Figure out How to Put resources into Lab Precious stones
- Al-Sharaa denies he called for 80% of Syrians to return from Germany
- Pick Your Favored kind of soup
- I served on the expert committee that advised the government on new dietary guidelines – most of our recommendations were ignored
- 8 Espresso Bean Starting points All over the Planet
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- FDA claims on COVID-19 vaccine safety are unsupported by reliable data – and could severely hinder vaccine access
